Men's Health News

RSS

BIDMC physician-scientist receives Young Investigator Award to research on prostate cancer

Akash Patnaik, MD, PhD, a physician-scientist in the Hematology/Oncology Divison at Beth Israel Deaconess Medical Center and Instructor of Medicine at Harvard Medical School has received a Young Investigator Award from The Prostate Cancer Foundation. The three-year $225,000 award, one of 21 made to young scientists from across the U.S. and Canada, is designed to encourage the most innovative minds in cancer research to focus their careers on prostate cancer.

1 Jul 2010

AMS granted 510(k) clearance for MoXy Liquid Cooled Fiber

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the 510(k) clearance of its revolutionary MoXy™ Liquid Cooled Fiber.

1 Jul 2010

Claros point-of-care system for PSA receives European CE Mark approval

Claros Diagnostics, a developer of novel point-of-care in vitro diagnostic systems, today announced the CE Mark approval for its rapid quantitative point-of-care diagnostic platform, which can now be used for prostate specific antigen (PSA) testing throughout the European Union. The approved system consists of a small portable analyzer and credit card-sized disposable.

29 Jun 2010

Study: Statins can reduce risk of prostate cancer recurrence after surgery

Men who use statins to lower their cholesterol are 30 percent less likely to see their prostate cancer come back after surgery compared to men who do not use the drugs, according to researchers at Duke University Medical Center. Researchers also found that higher doses of the drugs were associated with lower risk of recurrence.

29 Jun 2010

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

Reporting in the journal Urology, researchers at Thomas Jefferson University have found that a pre-emptive multimodal pain regimen that included pregabalin (Lyrica) decreased the use of opioid analgesics in patients undergoing robotic-assisted laparoscopic radical prostatectomy.

28 Jun 2010

Genomic analysis leads to more effective diagnostic tests, treatment options for prostate cancer: Study

A unique collaboration among physician-scientists at Memorial Sloan-Kettering Cancer Center has yielded the most comprehensive genomic analysis of prostate cancer to date. "Genomic studies in other cancer types have resulted in new drug targets and strategies to classify patients into clinically meaningful subgroups that improve treatment decisions," said senior study author Charles Sawyers, Chair of the Human Oncology and Pathogenesis Program at MSKCC and a HHMI investigator. "This first -ever database of its type brings us one step closer to achieving that goal in prostate cancer."

28 Jun 2010

PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration: Researchers

The way prostate cancer develops in men who have an altered 'breast cancer gene' is the same route by which breast cancer develops in women with the same mutation, reveals a study published in PLoS Genetics today (Thursday).

25 Jun 2010

Minnesota AIDS Project awarded federal grant to support HIV prevention services for young gay, bisexual men

The Minnesota AIDS Project is pleased to announce that it has been notified that it will be awarded a federal grant for five years totaling over $1.5 million from the Centers for Disease Control targeting HIV prevention services for young gay and bisexual men in Minnesota. This segment of the community represents the fastest growing population of HIV infections in Minnesota with the total number of new cases in 2009 at the highest level since 1994. The Minnesota AIDS Project Board of Directors is focusing its efforts to reduce these numbers and is committed to using the funds to target these prevention services.

25 Jun 2010

Researchers develop new assay test for bladder cancer

Researchers from the Danish Cancer Society and the Herlev University Hospital of Copenhagen have developed a novel assay to test for multiple tumor markers in bladder cancer.

25 Jun 2010

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Palatin Technologies, Inc. today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter.

24 Jun 2010

AVIS donates health research project focuses on cancer biomarkers

The greatest research project on cancer biomarkers is to start in the next months. The new scientific research will open new frontiers in the field of prevention of two most relevant cancer: prostate cancer and ovarian cancer. The research project, which also includes an important prevention programme, is named "AVIS donates health" (AVIS is the Italian most important blood donors association) and is supported by Fondazione Abo - Application of biotechnologies in Oncology, Avis, Lilt (Italiana League for the fight against cancer) and by the three scientific societies of gynecologists and urologists.

24 Jun 2010

Female biology screens for the best sperm: Study

A new study has revealed that the female reproductive system is ‘choosy’ when it comes to inferior quality sperm and rejects the ‘advances’ of spermatozoa that are not good enough to create a pregnancy.

23 Jun 2010

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy.

23 Jun 2010

Study shows monitoring can be the best treatment for men with prostate cancer of low-risk type

Monitoring can be the best treatment for men with prostate cancer of the low-risk type, according to a study now being published in the Journal of the National Cancer Institute. The lead author is Pär Stattin, a urologist at Umeå University.

23 Jun 2010

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.

23 Jun 2010

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

In an article to be published on 21 June 2010 in the Journal of Clinical Oncology, researchers from Inserm (Inserm unit 625 - Research Group on Human and Mammalian Reproduction, University of Rennes 1), the CHU (University Hospital Centre) in Pointe - Pitre (urology department, University of the French West Indies and Guiana) and from the Center for Analytical Research and Technology (University of Li-ge, Belgique), show that exposure to chlordecone (also named Kepone), an organochlorine chemical with well defined estrogenic properties used in the French West Indies until 1993, is associated to a significant increased risk of prostate cancer.

23 Jun 2010

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.

21 Jun 2010

Active surveillance sufficient for patients with low-risk prostate cancer

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.

19 Jun 2010

Data shows younger, unmarried men are least aware of hypertension

Younger, unmarried men around the world are least likely to be aware of hypertension (high blood pressure) and less likely to be receiving treatment. Whereas older women, are most aware of hypertension according to data presented today at the World Congress of Cardiology Scientific Sessions in Beijing, China.

19 Jun 2010

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

The Association of Minor League Umpires and its parent organization, Office and Professional Employees International Union, have partnered with "Ed Randall's Bat for the Cure – Strike Out Prostate Cancer" to raise funds for the fight against prostate cancer. This Father's Day weekend, June 19-20, the minor league umpires open their personal checkbooks and donate 1 cent for every pitch thrown in their Minor League Baseball games.

19 Jun 2010

Men's Health News

BIDMC physician-scientist receives Young Investigator Award to research on prostate cancer

AMS granted 510(k) clearance for MoXy Liquid Cooled Fiber

Claros point-of-care system for PSA receives European CE Mark approval

Study: Statins can reduce risk of prostate cancer recurrence after surgery

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

Genomic analysis leads to more effective diagnostic tests, treatment options for prostate cancer: Study

PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration: Researchers

Minnesota AIDS Project awarded federal grant to support HIV prevention services for young gay, bisexual men

Researchers develop new assay test for bladder cancer

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

AVIS donates health research project focuses on cancer biomarkers

Female biology screens for the best sperm: Study

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Study shows monitoring can be the best treatment for men with prostate cancer of low-risk type

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Exposure to chlordecone associated to increased risk of prostate cancer: Researchers

OncoGenex initiates Phase 3 Prostate Cancer SATURN Trial

Active surveillance sufficient for patients with low-risk prostate cancer

Data shows younger, unmarried men are least aware of hypertension

AMLU, OPEIU partner with Ed Randall's Bat for the Cure to raise funds for fight against prostate cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News